AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Castle Biosciences, Inc.
Video analysis: CSTL
All videosNo video analysis for this stock yet. Request one from our team.
News: CSTL
JAAD Publication Shows Improved Performance of DecisionDx®-SCC
DecisionDx-SCC shows enhanced performance with the integration of select clinicopathologic risk factors, providing a more precise result to support risk-aligned patient management DecisionDx-SCC's Class 1A (low risk) result demonstrated a 97.3% negative predictive value, supporting confidence in de-escalation decisions, while its Class 2B (highest risk) result identified patients most likely to benefit from adjuvant radiation therapy FRIENDSWOOD, Texas, Sept. 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a multi-center study in the Journal of the American Academy of Dermatology (JAAD) validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma (SCC).1 DecisionDx-SCC analyzes 40 genes to provide results related to prognosis and response to adjuvant radiation therapy (ART) based on an individual patient's tumor biology.
SciBase receives additional order from Castle Biosciences, advancing the collaboration
STOCKHOLM, Sept. 8, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received an additional order for an acceleration of the current, ongoing clinical study and preparations for a second clinical study under the collaboration with Castle Biosciences.
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?
The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m.
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary listing on The Nasdaq Global Market, and its common stock is expected to begin listing on Nasdaq Texas today under its existing ticker symbol, "CSTL.
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
Castle Biosciences NASDAQ: CSTL reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its reported beat, according to CFO Frank Stokes.
Comparing Gaxos.ai (NASDAQ:GXAI) and Castle Biosciences (NASDAQ:CSTL)
Castle Biosciences (NASDAQ: CSTL - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Earnings and Valuation This table compares Castle Biosciences
